Design, Synthesis, and Biological Evaluation of Novel Aminobisphosphonates Possessing an in Vivo Antitumor Activity Through a γδ-T Lymphocytes-Mediated Activation Mechanism

被引:69
作者
Simoni, Danicle [8 ]
Gebbia, Nicola [1 ]
Invidiata, Francesco Paolo [2 ]
Eleopra, Marco [8 ]
Marchetti, Paolo [8 ]
Rondanin, Riccardo [8 ]
Baruchello, Riccardo [8 ]
Provera, Stefano [3 ]
Marchicro, Carla [3 ]
Tolomeo, Manho [4 ]
Marinelli, Luciana [5 ]
Limongelli, Vittorio [5 ]
Novellino, Ettore [5 ]
Kwaasi, Aaron [6 ]
Dunford, James [6 ]
Buccheri, Siniona [7 ]
Caccamo, Nadia [7 ]
Dieli, Francesco [7 ]
机构
[1] CoRiBiA, Palermo, Italy
[2] Univ Palermo, Dipartimento Farmacochim Tossicol & Biol, I-90133 Palermo, Italy
[3] GlaxoSmithKline, Med Res Ctr, Verona, Italy
[4] Univ Palermo, Div Ematol Serv AIDS Policlin, Palermo, Italy
[5] Univ Naples Federico II, Dipartimento Chim Farmaceut & Tossicol, I-80131 Naples, Italy
[6] Univ Oxford, Nuffield Dept Orthopaed Surg, Nuffield Orthopaed Ctr, Botnar Res Ctr,Inst Musculoskeletal Sci, Oxford OX3 7LD, England
[7] Univ Palermo, Dipartimento Biopatol & Metodol Biomed, Palermo, Italy
[8] Univ Ferrara, Dipartimento Sci Farmaceut, I-44100 Ferrara, Italy
关键词
D O I
10.1021/jm801003y
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A small series of aminobisphosphonates (N-BPs) structurally related to zoledronic acid was synthesized with the aim of improving activity toward activation of human gamma delta T cells and in turn their in vivo antitumor activity. The absence of the 1-OH moiety, together with the position and the different basicity of the nitrogen, appears crucial for antitumor activity. In comparison to zoledronic acid, compound 6a shows a greater ability to activate gamma delta T cells expression (100 times more) and a proapoptotic effect that is better than zoledronic acid. The potent activation of gamma delta T cells, in addition to evidence of the in vivo antitumor activity of 6a, suggests it may be a new potential drug candidate for cancer treatment.
引用
收藏
页码:6800 / 6807
页数:8
相关论文
共 42 条
[21]   The molecular mechanism of nitrogen-containing bisphosphonates as anti osteoporosis drugs [J].
Kavanagh, Kathryn L. ;
Guo, Kunde ;
Dunford, James E. ;
Wu, Xiaoqiu ;
Knapp, Stefan ;
Ebetino, Frank H. ;
Rogers, Michael J. ;
Russell, R. Graham G. ;
Oppermann, Udo .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (20) :7829-7834
[22]   The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate [J].
Kuroda, J ;
Kimura, S ;
Segawa, H ;
Kobayashi, Y ;
Yoshikawa, T ;
Urasaki, Y ;
Ueda, T ;
Enjo, F ;
Tokuda, H ;
Ottmann, OG ;
Maekawa, T .
BLOOD, 2003, 102 (06) :2229-2235
[23]   Sequential application of chemotherapy and monoclonal CD 20 antibody: Successful treatment of advanced composite-lymphoma [J].
Linck, D ;
Lentini, G ;
Tiemann, M ;
Fauser, AA ;
Parwaresch, R ;
Basara, N .
LEUKEMIA & LYMPHOMA, 2005, 46 (02) :285-288
[24]   Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum:: A potential route to chemotherapy [J].
Martin, MB ;
Grimley, JS ;
Lewis, JC ;
Heath, HT ;
Bailey, BN ;
Kendrick, H ;
Yardley, V ;
Caldera, A ;
Lira, R ;
Urbina, JA ;
Moreno, SNJ ;
Docampo, R ;
Croft, SL ;
Oldfield, E .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (06) :909-916
[25]   Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vγ2Vδ2 T cells:: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens [J].
Morita, Craig T. ;
Jin, Chenggang ;
Sarikonda, Ghanashyam ;
Wang, Hong .
IMMUNOLOGICAL REVIEWS, 2007, 215 :59-76
[26]  
Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO
[27]  
2-B
[28]   Molecular mechanisms of action of bisphosphonates [J].
Rogers, MJ ;
Frith, JC ;
Luckman, SP ;
Coxon, FP ;
Benford, HL ;
Mönkkönen, J ;
Auriola, S ;
Chilton, KM ;
Russell, RGG .
BONE, 1999, 24 (05) :73S-79S
[29]   Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs [J].
Rondeau, Jean-Michel ;
Bitsch, Francis ;
Bourgier, Emmanuelle ;
Geiser, Martin ;
Hemmig, Rene ;
Kroemer, Markus ;
Lehmann, Sylvie ;
Ramage, Paul ;
Rieffel, Sebastien ;
Strauss, Andre ;
Green, Jonathan R. ;
Jahnke, Wolfgang .
CHEMMEDCHEM, 2006, 1 (02) :267-273
[30]   Bisphosphonates: From the laboratory to the clinic and back again [J].
Russell, RGG ;
Rogers, MJ .
BONE, 1999, 25 (01) :97-106